5-phenyl-1,2,3,4-tetrahydro-(5H)-2-benzazepine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 英文名称: 5-phenyl-1,2,3,4-tetrahydro-(5H)-2-benzazepine
• 英文别名: 5-phenyl-2,3,4,5-tetrahydro-1H-2-benzazepine
• 化学式: C₁₆H₁₇N
• 分子量: 223.318
• InChiKey: KDLFIMMJZAPLLA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  3-(甲基硫代)苯甲醛 在 sodium tetrahydroborate 、 nickel dichloride 作用下， 反应 33.0h， 生成 5-phenyl-1,2,3,4-tetrahydro-(5H)-2-benzazepine
  参考文献：
  名称：

  Euerby, Melvin R.; Waigh, Roger D., Journal of Chemical Research, Miniprint, 1987, # 2, p. 554 - 575

  摘要：

  DOI：

文献信息

• Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
  申请人：Molino F. Bruce

  公开号：US20070021408A1

  公开（公告）日：2007-01-25

  The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R 1 -R 9 are as defined herein.

  本发明的化合物由以下具有式I(A-E)和式(II)的芳基和杂芳基取代的四氢苯并哌啶和二氢苯并哌啶衍生物表示：其中指定为*的碳原子处于R或S构型，取代基X和R1-R9如本文所定义。
• ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN
  申请人：MOLINO Bruce F.

  公开号：US20090118260A1

  公开（公告）日：2009-05-07

  The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II): where the carbon atom designated * is in the R or S configuration, and the substituents X and R 1 -R 9 are as defined herein.

  本发明的化合物由以下具有式I（A-E）和式II的芳基和杂芳基取代的四氢苯并咪唑和二氢苯并咪唑衍生物表示：其中指定*的碳原子处于R或S构型，取代基X和R1-R9如本文所定义。
• TETRAHYDROBENZINDOLE DERIVATIVES
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：EP1057814A1

  公开（公告）日：2000-12-06

  This invention creates compounds represented by the following formula (1) which, alone or as a plurality of them simultaneously, act upon serotonin receptors, and thereby provides pharmaceutical compositions that contain these compounds and are useful for the treatment or prevention of diseases which are considered to be induced by the abnormality of central and peripheral serotonin controlling functions. In the formula, R1 is a hydrogen atom, a lower alkyl group or an aralkyl group; R2 is a hydrogen atom or a specified substituent; n is an integer of 2 to 6; and α is the following formula (a), (b), (c), (d) or (e). In formulae (a) and (b), R3 is a hydrogen atom or a specified substituent; X is NR10, NCONR11R12, S, SO, SO2 or O; R10 is a hydrogen atom or a specified substituent; R11 and R12 is independently a hydrogen atom or a lower alkyl; Y is a methylene group or a carbonyl group. In formula (c), R4 is a hydrogen atom or a specified substituent; R5 is a hydrogen atom or a specified substituent; k is 0 or an integer of 1 to 3; m is 0 or an integer of 1 to 3; each of A and B is a group which forms a specified ring via a double bond; k + m is an integer of 1 to 3. In formulae (d) and (e), R4 is as defined above; G is CH2, S, O or C=O; D is CH or N; p is an integer of 1 to 3; each of E and J is a group which forms a benzene ring or a pyridine ring via a double bond; R6 and R7 is independently a hydrogen atom or a lower alkyl or the like specified substituent.

  本发明创造了由下式(1)表示的化合物，这些化合物单独或多个同时作用于血清素受体，从而提供了含有这些化合物的药物组合物，这些组合物可用于治疗或预防被认为是由中枢和外周血清素控制功能异常诱发的疾病。 式中，R1 是氢原子、低级烷基或芳烷基；R2 是氢原子或特定取代基；n 是 2 至 6 的整数；α 是下式 (a)、(b)、(c)、(d) 或 (e)。 在式(a)和(b)中，R3 是氢原子或特定取代基；X 是 NR10、NCONR11R12、S、SO、SO2 或 O；R10 是氢原子或特定取代基；R11 和 R12 独立地是氢原子或低级烷基；Y 是亚甲基或羰基。在式(c)中，R4 是氢原子或特定取代基；R5 是氢原子或特定取代基；k 是 0 或 1 至 3 的整数；m 是 0 或 1 至 3 的整数；A 和 B 各自是通过双键形成特定环的基团；k + m 是 1 至 3 的整数。在式(d)和(e)中，R4 如上定义；G 是 CH2、S、O 或 C＝O；D 是 CH 或 N；p 是 1 至 3 的整数；E 和 J 各自是通过双键形成苯环或吡啶环的基团；R6 和 R7 独立地是氢原子或低级烷基或类似的指定取代基。
• The acid-mediated ring opening/cyclisation reaction of N-benzyl-α-aryl-azetidinones
  作者：Frank D. King、Stephen Caddick

  DOI：10.1016/j.tet.2012.09.046

  日期：2012.11

  N-Benzyl-4-aryl-azetidinones undergo ring opening with triflic acid to form N-benzyl-cinnamamides, which either undergo cyclisation to give 5-aryl-benzazepin-3-ones or N-debenzylation to give cinnamamides. (C) 2012 Elsevier Ltd. All rights reserved.
• Euerby, Melvin R.; Waigh, Roger D., Synthetic Communications, 1986, vol. 16, # 7, p. 779 - 784
  作者：Euerby, Melvin R.、Waigh, Roger D.

  DOI：——

  日期：——